Watchdog: Biogenerics needed 'as quickly as possible'

As the FDA hashes out issues on regulating knockoffs of biotech drugs, or what the industry calls biosimilars, the consumer advocacy group Public Citizen makes a case in a Chicago Tribune story this week about the need for generic versions of pricey biologics. "Biotech drugs are among the world's most expensive," Sidney Wolfe, director of the health research group at Public Citizen, told the newspaper. "They have been good, but they have been expensive, so it is extraordinarily important to get biogenerics as quickly as possible." Article

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spin-out company SpringWorks has lost president and founder Lara Sullivan, M.D. who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.